Published in Memo on October 28, 2016
Targeting the PD-1 pathway in pediatric solid tumors and brain tumors. Onco Targets Ther (2017) 0.75
Association between PD-L1 and HPV status and the prognostic value for HPV treatment in premalignant cervical lesion patients. Medicine (Baltimore) (2017) 0.75
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med (2012) 52.99
Cancer genome landscapes. Science (2013) 25.33
Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature (2013) 20.16
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med (2015) 12.54
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature (2014) 12.00
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med (2015) 11.98
Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med (2015) 10.12
Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncol (2015) 5.95
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet (2015) 5.42
Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer. J Clin Oncol (2015) 4.68
Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet (2016) 4.12
Classifying Cancers Based on T-cell Infiltration and PD-L1. Cancer Res (2015) 1.77
Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. Lancet Oncol (2016) 1.55
Programmed Death-Ligand 1 Immunohistochemistry in Lung Cancer: In what state is this art? J Thorac Oncol (2015) 1.48
Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer. J Clin Oncol (2016) 1.35
Nivolumab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer. J Clin Oncol (2016) 1.24
Nivolumab in Combination With Platinum-Based Doublet Chemotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer. J Clin Oncol (2016) 1.24
Harnessing the immune system for the treatment of non-small-cell lung cancer. J Clin Oncol (2013) 1.22
Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer--response. Clin Cancer Res (2013) 1.11
Harmonized PD-L1 immunohistochemistry for pulmonary squamous-cell and adenocarcinomas. Mod Pathol (2016) 1.04
PD-1/PD-L1 blockade in cancer treatment: perspectives and issues. Int J Clin Oncol (2016) 0.95
PD-L1 expression as predictive biomarker in patients with NSCLC: a pooled analysis. Oncotarget (2016) 0.93
Programmed Death Ligand-1 Immunohistochemistry- A New Challenge for Pathologists: A Perspective From Members of the Pulmonary Pathology Society. Arch Pathol Lab Med (2016) 0.91
Non-Small Cell Lung Cancer, PD-L1, and the Pathologist. Arch Pathol Lab Med (2016) 0.90
Programmed Death Ligand-1 Immunohistochemistry: Friend or Foe? Arch Pathol Lab Med (2016) 0.90
PD-1-targeted immunotherapy: recent clinical findings. Clin Adv Hematol Oncol (2012) 0.88
Predictive Biomarkers for PD-1 Axis Therapies: The Hidden Treasure or a Call for Research. Clin Cancer Res (2016) 0.82
Preanalytics in lung cancer. Recent Results Cancer Res (2015) 0.82
"Companion diagnostics": has their time come and gone? Clin Cancer Res (2014) 0.81
The pre-analytical phase in surgical pathology. Recent Results Cancer Res (2015) 0.80